Novel intrasaccular aneurysm treatment device receives FDA PMA approval

The WEB® Aneurysm Embolization System is the first intrasaccular flow disruptor PMA approved for the embolization of wide neck bifurcation aneurysmsAliso Viejo, CA. – January 7, 2019 – MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Premarket Approval (PMA) for the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB System is the first and only PMA approved device in the new category of intrasaccular flow disruptors for aneurysm embolization. (The WEB System was developed by Sequent Medical, Inc. and Sequent was acquired by Terumo in 2016).


Cerenovus launches largest global registry to study stroke-inducing bloo...

Company Also Receives European CE Mark Approval for Novel Stroke Technology Designed for Difficult to Extract Blood ClotsIRVINE, Calif., Dec. 10, 2018 -- Johnson & Johnson Medical Devices Companies* today announced that its CERENOVUS business has launched the single largest global registry, the EXCELLENT Registry, to collect and analyze stroke-inducing blood clots removed from the brain with its EMBOTRAP II Revascularization Device, a next generation stent retriever used in mechanical thrombectomy.


World Stroke Day -- SVIN latest clinical trials and breaking science news

Minneapolis, Minnesota (October 29, 2018) - Society of Vascular and Interventional Neurology's 2018 annual meeting to showcase breakthrough technology on stroke thrombectomy offering a ray of hope for stroke patients worldwide. The results of latest clinical trials and breaking science news related to the use of vacuum aspiration for removing blood clots in stroke patients will be presented at the upcoming SVIN annual meeting in San Diego.


BALT International announces CE Mark of the MAGIC GLUE next generation o...

Paris, France, October 3rd, 2018 – BALT International announced today that it has received CE Mark for MAGIC GLUE, its next generation of cyanoacrylate liquid embolic agent.


MicroVention® announces FDA Clearance for thrombectomy device

SOFIA® Catheter; A New Device for the Revascularization of Patients with Acute Ischemic Stroke


Sensome raises €4.6 million to bring the first connected stroke device t...

Paris, France – Sensome, the company pioneering the connected medical device revolution with the world’s smallest sensor to identify biological tissues, announced today the successful completion of a new 4.6 million euro financing round to bring the Clotild™ smart stroke guidewire to market. Kurma Partners led the existing venture capital syndicate (Paris-Saclay Seed Fund, Idinvest) and other historical investors and was joined by venture capital firm BNP Paribas Developpement.


MicroVention® Announces FDA Approval For Neuro Stent Device

MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Premarket Approval (PMA) for the LVIS® and LVIS® Jr. stents for stent-assisted coil embolization of intracranial aneurysms. The LVIS® and LVIS® Jr. stents are the first and only stents PMA approved for stent-assisted coil embolization and only the second PMA approved device designed for intracranial aneurysm treatment.


New study shows use of EMBOTRAP® device clot retriever during treatment...

ARISE II Clinical Trial Results Published in Stroke Journal  Gothenburg, Sweden – May 16, 2018 –EMBOTRAP® Device, a device designed to remove clots from the brain following an ischemic stroke, demonstrated high success rates in restoring blood flow and patients achieved high rates of functional independence, according to ARISE II (Analysis of Revascularization in Ischemic Stroke with EMBOTRAP® Device), a new clinical trial published in Stroke [Journal]. 


CERENOVUS receives FDA clearance for next generation stent retriever dev...

EMBOTRAP II Revascularization Device Captures and Removes Life-threatening Blood Clots, Rapidly Restores Blood Flow IRVINE, California, May 21, 2018 - CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EMBOTRAP II Revascularization Device, a next generation stent retriever used to capture and remove life-threatening blood clots from the brain following an ischemic stroke.

PRESS RELEASE to present expanded data on ALADIN and new data on ADVANCE expand...

Breadth of ALADIN data to reinforce results in expanded scans across multiple centers Important research will highlight a potential use case for’s deep learning, artificial intelligence algorithms beyond acute ischemic stroke.